Soleno Therapeutics, Inc. (SLNO)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Soleno Therapeutics, Inc. (SLNO)
Go deeper and ask any question about SLNO
Company Performance
Current Price
as of Sep 13, 2024$52.84
P/E Ratio
N/A
Market Cap
$2.05B
Description
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Metrics
Overview
- HQRedwood City, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerSLNO
- Price$52.84+6.51%
Trading Information
- Market Cap$2.05B
- Float66.61%
- Average Daily Volume (1m)621,655
- Average Daily Volume (3m)542,547
- EPS-$2.43
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$21.85M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$22.74M
- EV$1.31B
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account